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1  Introduction 
This Therapeutic Area Data Standards User Guide for Multiple Sclerosis (TAUG-Multiple Sclerosis) was developed 
under the Coalition for Accelerating Standards and Therapies (CFAST) initiative. 
 
CFAST, a joint initiative of CDISC and the Critical Path Institute (C-Path), was launched to accelerate clinical 
research and medical product development by facilitating the establishment and maintenance of data standards, 
tools, and methods for conducting research in therapeutic areas important to public health. CFAST partners include 
TransCelerate BioPharma Inc. (TCB), the U.S. Food and Drug Administration (FDA), and the National Cancer 
Institute Enterprise Vocabulary Services (NCI EVS), with participation and input from many other organizations.  
1.1 Purpose 
This document comprises Version 1.0 (v1.0) of the Multiple Sclerosis-specific Therapeutic Area User Guide 
(TAUG-Multiple Sclerosis) to be used as a supplement to the CDISC Study Data Tabulation Model (SDTM) and the 
SDTM Implementation Guide for Human Clinical Trials (SDTMIG). This user guide was prepared by the CFAST 
Multiple Sclerosis Development Team, with participation from the Critical Path Institute’s Multiple Sclerosis 
Outcome Assessments Consortium (MSOAC), using common data elements developed by the National Institute for 
Neurological Disorder and Stroke (NINDS) as inputs. It is intended to guide the organization, structure, and format 
of standard multiple sclerosis (MS) clinical trial tabulation datasets submitted to a regulatory authority such as the 
FDA.  
 
With regard to clinical trials of MS, this guide describes a specific implementation of a subset of the domains whose 
general implementation guidelines are described in the current version of the SDTMIG. This document also makes 
use of newly drafted SDTM-based domains, and shows rules for and examples of implementing these domains 
specifically for trials of MS. 
 
This document does not replace, supersede, nor otherwise override any rules or requirements of the current 
SDTM and SDTMIG. Knowledge of this document alone is not a substitute for knowledge of SDTM nor is it 
sufficient to produce complete, SDTM-compliant regulatory submissions of MS clinical trial data. The TAUG-
Multiple Sclerosis v1.0 should be used in close concert with the current version of the SDTMIG and the current 
version of the CDISC Study Data Tabulation Model (available at http://www.cdisc.org/standards). The SDTM 
describes the general model for representing clinical study data that is submitted to regulatory authorities and should 
be read prior to reading the SDTMIG. An understanding of both of these documents is required before attempting to 
read and understand the TAUG-Multiple Sclerosis v1.0. 
 
This document is intended for companies and individuals involved in the collection, preparation, and analysis of MS 
clinical data that will be submitted to regulatory authorities. 
 
Domains for which there are no current MS-specific implementation examples are not included in this document. 
For information on these domains, refer to the current version of the SDTM/SDTMIG and other CDISC 
supplemental guides.  
1.2 Organization of this Document 
This TAUG-Multiple Sclerosis v1.0 follows the style of therapeutic area user guides developed under the CFAST 
initiative that have a more clinically oriented organization. 
 
•  Section 1, Introduction, provides an overall introduction to the purpose and goals of this project.  
•  Section 2, Subject and Disease Characteristics, covers data that are usually collected once at the beginning 
of a study, and clinical events relevant to disease progression. 
•  Section 3, Disease Assessments, covers data that are used to evaluate disease severity, control, or 
progression. These are usually collected repeatedly during a study, and may be used as efficacy endpoints. 
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•  Section 4, Additional Assumptions for Domains, provides the MS-specific assumptions for the domains 
included in this document. 
•  Appendices provide additional background material and describe other supplemental material relevant to 
MS.  
 
A list of domains used in the examples in this document, and the sections in which they appear, is given below:  
 
Domains from SDTMIG  Section(s) 
Events 
CE – Clinical Events  2.2.1 
MH – Medical History  2.1.1, 2.2.1 
Findings 
MO – Morphology  3.2.1.1 
NV – Nervous System Findings*  3.3.1 
OE – Ophthalmic  Exams *  3.1.1 
Findings About Events or Interventions 
FA – Findings About   2.1.1, 2.2.1 
Trial Design Data Sets 
TS – Trial Summary  2.1.1, 2.2.1 
* Domain was not published in SDTMIG 3.2 and is not final.  
 
Domains from SDTMIG-MD*  Section(s) 
DI – Device Identifiers  3.2.1.1, 3.3.1  
DU – Device In-Use  3.3.1 
*SDTMIG for Medical Devices 
 
A list of draft findings variables used in this document, and the sections in which they appear, is given below: 
 
Variable Name  Variable Label  Type  Role  Description  Section 
--REST  Reference Term 
for the Result 
Char  Synonym Qualifier 
of --ORRES and -
-STRESC 
The name or code for the 
result according to a 
reference terminology.  
2.1.1 
--RESTNM  Result Reference 
Terminology 
Name 
Char  Variable Qualifier of 
–REST 
The name of the reference 
terminology used to 
populate --REST. May be a 
codelist, nomenclature, or 
database.  
2.1.1 
--RESTVR  Result Reference 
Terminology 
Version 
Char  Variable Qualifier of 
--RESTNM 
The version of the 
reference terminology 
specified in --RESTNM.  
2.1.1 
 
1.3 Concept Maps 
This document uses concept maps to explain clinical processes and research concepts. Concept maps, also 
sometimes called mind maps, are diagrams which include “bubbles” representing concepts/ideas/things and labeled 
arrows that represent the relationships between the concepts/ideas/things. They are generally easier to draw and 
more accessible than more formal modeling diagrams, such as Universal Modeling Language (UML) diagrams. 
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Concept Classification Key for Concept Maps 
   
The diagrams in this document use the following coding for classification of concepts. This classification is based 
on classes in the Biomedical Research Integrated Domain Group (BRIDG) model. These color-symbol pairs have 
been used to highlight kinds of things that occur commonly in clinical data and therefore give rise to common 
patterns of data. Some concepts are not coded; they have a thinner, black outline, and no accompanying symbol. 
These may include the subject of an observation, as well as characteristics, or attributes, of the coded concepts.  
 
1.4 Controlled Terminology 
CDISC controlled terminology is published by the National Cancer Institute’s Enterprise Vocabulary Services (NCI 
EVS) and is available at: http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/cdisc.  
 
Production terminology is updated quarterly. Because this document is a static publication, it refers readers to the 
NCI EVS page for CDISC terminology (at the link given above). For the same reason, this document cannot claim 
to use controlled terminology in the examples provided; users should not refer to these as the ultimate authority on 
what terms to use.  
1.5 Relationships to Other Standards 
This section describes the relationship of this document to other standards, whether CDISC or external. This 
document does not replace the foundational CDISC standards or their implementation guides. The user should read 
those standards and implementation guides before applying the advice in this user guide. 
 
The primary sources of inputs for the development of this TAUG-Multiple Sclerosis v1.0 were the NINDS Common 
Data Elements for MS. The scope was limited to the following areas: functional tests and questionnaires, visual 
acuity and contrast sensitivity, diagnosis and disease characteristics, relapse, optical coherence tomography (OCT), 
and visual evoked potential. Note that all functional tests and questionnaires implemented for MS are maintained as 
standalone supplements on the CDISC website. See Section 3.4 for details. 
 
This document uses the Nervous System Findings (NV) and the Ophthalmic Examinations (OE) domains, which are 
draft domains. As draft domains, they not final at the time of publication, and are therefore subject to change or 
deletion without formal notice. Please check the most recent version of the SDTM and SDTMIG to ascertain their 
current status. 
 
In some cases when a definitive SDTM modeling approach does not exist, a suggested approach is offered but may 
be subject to change over time.  
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There are multiple types of data that have existing CDASH and SDTM-based standards that can be used in MS 
studies without additional development or customization, such as Demographics, Adverse Events, Clinical Events, 
and Concomitant Medications. Domains whose uses are not explicitly represented in the examples within this 
document can still be used according to the rules of those domains as needed. Refer to the current SDTMIG for 
implementation examples using those domains. 
 
2  Subject and Disease Characteristics 
2.1 Medical History and Disease Course 
This section describes various concepts in MS medical history and disease course, including symptoms, unifocal vs. 
multifocal disease, and diagnostic criteria. 
 
Onset of Disease Symptoms 
 
The onset of MS is difficult to determine precisely. The initial symptom(s) that typically mark onset of disease, such 
as visual disturbance, numbness, weakness, or tingling may be vague. If a neurologic assessment is obtained at this 
point, most patients who go on to be diagnosed with MS will present with a clinically isolated syndrome (CIS) 
manifesting as a single attack of the optic nerve, brain, or spinal-cord.  Conventional magnetic resonance imaging 
(MRI) performed at this time may reveal white matter lesions in a single region of the brain or spinal cord. 
Sometimes multiple regions will be involved. When lesions suggestive of MS are observed on MRI scans in the 
absence of a confirmed diagnosis of MS, these individuals may be identified as having a radiologically isolated 
syndrome (RIS). The onset course of MS can be unifocal or multifocal. Unifocal onset involves a single lesion in 
one region of the central nervous system (CNS). Multifocal onset involves multiple lesions in one or more regions of 
the CNS. Other diagnostic tests that may help determine if a patient has MS and rule out alternative diagnoses 
include the analysis of cerebrospinal fluid (CSF) and serum, as well as a variety of functional and visual assessment 
scales that are described in the Disease Assessment section of this guide. 
 
Disease Course 
 
The progression of MS can be variable following onset, and may worsen during disease course. Three common 
subtypes of MS have recently been described by the MS Phenotype Group under the auspices of the International 
Advisory Committee on Clinical Trials in MS (supported by the European Committee for Treatment and Research 
in Multiple Sclerosis (ECTRIMS) and the National MS Society)1. These subtypes are relapsing-remitting (RRMS), 
primary progressive (PPMS), and secondary progressive (SPMS). Disease activity, based on clinical relapse rate and 
imaging findings, is an important modifier of the core MS phenotype descriptions of relapsing and progressive 
disease.  Most patients will recover from the initial event and then go on to have relapses months or even years later. 
This clinical course is defined as RRMS. Patients with RRMS frequently convert to SPMS later in the disease 
process. Patients who continue to have a steady decline after the initial event symptoms are said to have PPMS. For 
more information on relapse, see Section 2.2 below. 
 
An additional subtype of MS was included in the 1996 Lublin-Reingold clinical course definitions2: progressive 
relapsing (PRMS).  Patients who experienced a steady decline with intermittent relapses were considered to have 
PRMS. This subtype has been eliminated by the MS Phenotype Group (2014), because subjects categorized in the 
past as PRMS would now be classified as PPMS with disease activity. 
 
This section shows examples for representing a disease course that was initially relapsing-remitting (RRMS) then 
converted to secondary progressive (SPMS). Figure 2.1-1 below shows a graphical representation of the three 
common subtypes of MS based on the characteristics of their respective disease courses. 
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Figure 2.1-1: Characteristics of the progression of the three common subtypes of MS 
 
 
Diagnostic Criteria 
 
The diagnosis of MS is typically made on the basis of a set of objective clinical criteria, which may be supplemented 
with other data obtained from MRI scans and CSF analysis.  The clinical presentation of MS is highly variable, 
relying on patient reported or objectively observed sensory, visual, or motor signs and symptoms that reflect 
neurological damage and that have been documented by a neurological exam and findings from visual evoked 
potential testing or MRI.  
 
The currently used diagnostic criteria – the McDonald Criteria – were originally proposed in 2001 and have since 
been updated in both 2005 and 20103, 4, 5. These criteria require the demonstration of brain lesions disseminated 
across both time and space. In other words, there must be multiple CNS regions affected, and at more than one time. 
The McDonald Criteria integrate MRI scanning into the diagnosis across varying presentations. 
 
The individual criteria met to make the same diagnosis (e.g., RRMS) for two subjects may not always be precisely 
the same. Knowing which criteria were met to reach a definitive diagnosis may be important for analysis. The 
examples below show how to represent these criteria in the SDTM in different scenarios.
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Figure 2.1-2: Concept Map of Medical History and Disease Course 
 
Table 1- MS Subtypes for Diagnosis Terms    Table 2- Examples of Initial Symptoms 
Relapsing Remitting Multiple Sclerosis    Sensory problems (numbness or tingling of a body part) 
Secondary Progressive Multiple Sclerosis (not valid for onset)     Weakness 
Primary Progressive Multiple Sclerosis    Fatigue 
    Difficulty walking 
    Monocular decreased vision 
    Poor coordination 
    Bladder problems 
    Bowel problems 
    Cognitive difficulties 
    Pain 
    Encephalopathy 
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2.1.1 Examples for Medical History and Disease Course 
 
For additional assumptions, see Section 4. 
 
Example 1 
The medical history of MS can include both a current and an onset disease course. In both cases, MHCAT is populated with the term “PRIMARY DIAGNOSIS”. 
MHSCAT is used to differentiate between onset course and current course. It may also be important to capture the initial symptoms of the onset course. Initial 
symptoms are categorized as “PRIMARY DIAGNOSIS” in MHCAT and “INITIAL SYMPTOMS” in MHSCAT. Localization and focus of the onset course 
should be recorded in FAMH.  
 
Rows 1, 4:  Show a subject enrolled in a study whose onset course of MS was relapsing remitting multiple sclerosis (Row 1) and whose current course is 
secondary progressive multiple sclerosis (Row 4).  
Rows 2-3:  Show the initial symptoms of the above subject that were related to the onset course. MHGRPID is used to link the initial symptoms to the onset 
course.  
 
mh.xpt 
Row STUDYID DOMAIN  USUBJID  MHSEQ MHGRPID  MHTERM  MHDECOD  MHCAT  MHSCAT 
1  ABC123  MH  MS01-101  1  1  RRMS  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE 
2  ABC123  MH  MS01-101  2  1  Double Vision  Diplopia  PRIMARY DIAGNOSIS  INITIAL SYMPTOMS 
3  ABC123  MH  MS01-101  3  1  Tingling  Paresthesia  PRIMARY DIAGNOSIS  INITIAL SYMPTOMS 
4  ABC123  MH  MS01-101  4    SPMS  Secondary Progressive Multiple Sclerosis  PRIMARY DIAGNOSIS  CURRENT COURSE 
 
Row  MHLOC  MHLAT  MHSTDTC 
1 (cont)      1999-03 
2 (cont)  EYE  BILATERAL  1999-02 
3 (cont)  ARM  LEFT  1998-12 
4 (cont)      2008-11 
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Several anatomical locations may be evaluated to determine the localization of the onset course. When the anatomical location is pre-specified, it is important to 
represent both the absence and presence of disease in that location. Additionally, the observation method used to examine a particular anatomical location may 
vary. In this scenario, Findings About Medical History (FAMH) should be used where FALOC represents the localization of disease onset, FAORRES represents 
the presence or absence of disease, and FAMETHOD represents the method of determining the localization of disease onset. These data should be linked to the 
onset course in MH via FAOBJ and FASCAT. If the subject has multiple onset localizations that are not pre-specified on a CRF, MHLOC should contain the 
term “MULTIPLE” with individual locations stored in SUPPMH (SDTMIG v3.2, Section 4.1.2.8.3 Multiple Values for a Non-Result Qualifier Variable). The 
focus of onset (e.g. unifocal or multifocal) should also be represented in FAMH. 
  
Rows 1-4:  Show the pre-specified localizations of the onset course, the presence or absence of disease at each anatomical location, and the method that was 
used to make that determination. The subject’s disease was localized to the optic nerve (as determined by MRI) and the cerebrum (as 
determined by exam). No evidence of disease was found in the other locations via the observation methods used. 
Row 5:  Shows that the onset course was multifocal. 
 
famh.xpt 
Row STUDYID  USUBJID  FASEQ  FATESTCD  FATEST  FAOBJ  FACAT  FASCAT  FAORRES 
1  ABC123  MS01-101  1  LOCONSET  Localization of Onset  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  Y 
2  ABC123  MS01-101  2  LOCONSET  Localization of Onset  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  N 
3  ABC123  MS01-101  3  LOCONSET  Localization of Onset  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  N 
4  ABC123  MS01-101  4  LOCONSET  Localization of Onset  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  Y 
5  ABC123  MS01-101  5  FOCUSON  Focus of Onset  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  MULTIFOCAL 
 
Row  FALOC  FAMETHOD  FADTC 
1 (cont)  OPTIC NERVE  MRI  1999-03 
2 (cont)  SPINAL CORD  PHYSICAL EXAM  1999-03 
3 (cont)  BRAINSTEM  MRI  1999-03 
4 (cont)  CEREBRUM  PHYSICAL EXAM  1999-03 
5 (cont)      1999-03 
 
The relationship between the diagnosis of MS and the localization of onset and onset focus are represented in RELREC. The RELREC table below shows how to 
relate records between MH and FA in MS diagnosis. 
 
Rows 1-2:  Link the diagnosis of MS to both the localization and the focus of onset. This indicates that the MHSCAT variable for a diagnosis of RRMS is 
linked to records in Findings About Medical History via the same value in the FASCAT variable.     
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  MH    MHSCAT    ONE  1 
2  ABC123  FAMH    FASCAT    MANY  1 
 
The example below uses domains and variables which are not final at the time of the publication of this document.  
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Example 2 
A diagnosis of MS is based on a set of diagnostic criteria. The level of detail collected about diagnostic criteria may vary across studies. For example, if a 
diagnosis of MS is based on the McDonald 2010 criteria, a subject can meet these criteria for diagnosis via several different sub-criteria based on clinical 
presentation, along with additional paraclinical evidence. In other words, “McDonald 2010” is not specific enough; the specific criterion met under the 
McDonald 2010 definitions should also be represented in the diagnostic criteria records. If diagnostic criteria are specified at the protocol level and do not vary 
between subjects, this information should be represented in the Trial Summary domain (TS). However, when diagnostic sub-criteria are captured and vary 
between subjects, these data should be represented at the subject level in the Findings About Medical History domain (FAMH) in addition to the trial-level 
information represented in TS. In the latter case, the records in TS give reviewers a snapshot of the various criteria met by subjects in the study, whereas the 
records in FAMH show which subjects met which specific diagnostic criterion. These subject-level records in FAMH should also be tied to the MS diagnosis 
record in MH via FALNKID and MHLNKID.  
 
The example below shows how to represent information about a diagnosis of RRMS. This same structure should be used to represent diagnostic criteria for other 
MS subtypes. 
 
Rows 1-2:  Show medical history records for two different subjects both diagnosed with RRMS.  
 
mh.xpt 
Row STUDYID DOMAIN  USUBJID  MHSEQ MHLNKID  MHTERM  MHDECOD  MHCAT  MHSCAT  MHSTDTC 
1  ABC123  MH  MS01-102  1  1  RRMS  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  2011-04-03 
2  ABC123  MH  MS01-103  1  1  RRMS  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  2011-11-16 
 
Representing Diagnostic Criteria at the Trial Level 
 
Row 1:  Show how to represent trial-level diagnostic criteria 
 
ts.xpt 
Row STUDYID  DOMAIN  TSSEQ  TSPARMCD  TSPARM  TSVAL 
1  ABC123  TS  1  DXCRIT  Diagnostic Criteria  MCDONALD 2010 
 
Representing Diagnostic Criteria at the Subject Level 
 
Rows 1-2:  Show how to represent subject-level diagnostic criteria information. In this example, each subject met the McDonald 2010 criteria through a 
different presentation and evidence of RRMS. The specific diagnostic sub-criterion met is represented in FAORRES/FAREST. The McDonald 
2010 criteria were used to obtain this diagnosis as indicated in the FARESTNM/FARESTVR values. FALNKID ties this record to the subject’s 
diagnosis of RRMS in the mh.xpt example above. In consideration of space and clarity, the expected variable FASTRESC is not shown. In this 
example, FASTRESC would hold the same value as FAORRES. 
 
famh.xpt 
Row STUDYID DOMAIN  USUBJID  FASEQ  FALNKID  FATESTCD  FATEST  FAOBJ 
1  ABC123  FAMH  MS01-102  1  1  DXCRITMT  Diagnostic Criteria Met  Relapsing Remitting Multiple Sclerosis 
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Row STUDYID DOMAIN  USUBJID  FASEQ  FALNKID  FATESTCD  FATEST  FAOBJ 
2  ABC123  FAMH  MS01-103  1  1  DXCRITMT  Diagnostic Criteria Met  Relapsing Remitting Multiple Sclerosis 
 
Row  FAORRES  FAREST  FARESTNM  FARESTVR 
1 (cont) 
Greater than or equal to 2 attacks; objective clinical 
evidence of greater than or equal to 2 lesions or objective 
clinical evidence of 1 lesion with reasonable historical 
evidence of a prior attack 
Greater than or equal to  2 attacks; objective clinical 
evidence of greater than or equal to 2 lesions or objective 
clinical evidence of 1 lesion with reasonable historical 
evidence of a prior attack 
MCDONALD  2010 
2 (cont) 
Greater than or equal to 2 attacks; objective clinical 
evidence of 1 lesion. Dissemination in space, demonstrated 
by greater than or equal to 1 T2 lesion in at least 2 of 4 MS-
typical CNS regions  
Greater than or equal to 2 attacks; objective clinical evidence 
of 1 lesion. Dissemination in space, demonstrated by greater 
than or equal to 1 T2 lesion in at least 2 of 4 MS-typical CNS 
regions 
MCDONALD  2010 
 
The RELREC table below shows how to preserve the relationship between the diagnosis of MS and the subject-level diagnostic criterion met. 
 
Rows 1-2:  Link the diagnosis of MS and the subject-level diagnostic criterion. This indicates that the MHLNKID variable for a diagnosis is linked to one 
FAMH record via the same value in the FALNKID variable.     
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  MH    MHLNKID    ONE  2 
2  ABC123  FAMH    FALNKID    ONE  2 
 
 
Example 3 
The example below shows two subjects who were diagnosed with MS using different versions of the McDonald criteria (2010 and 2005, respectively), as 
opposed to example 2 above where the subjects were diagnosed via the same version (2010), but different specific criteria. When the diagnostic criteria versions 
used vary at the subject level, the use of the TS domain alone is not sufficient; the subject-level criteria must be represented in Findings About in these cases. In 
this example, the RELREC table would mirror the example above. If the specific sub-criteria were not collected, FAORRES/FAREST should be populated with 
the appropriate version of the diagnostic criteria used (e.g. FAORRES/FAREST = “MCDONALD 2010”) while both FARESTNM and FARESTVR should still 
be populated (e.g. “MCDONALD” and “2010” respectively. In consideration of space and clarity, the expected variable FASTRESC is not shown. In this 
example, FASTRESC would hold the same value as FAORRES. 
 
Row 1:  Shows how to represent subject-level diagnostic criteria information. In this example, the subject met the McDonald 2010 criteria. The specific 
diagnostic sub-criterion met is represented in FAORRES/FAREST.  
Row 2:  Shows how to represent subject-level diagnostic criteria information. In this example, the subject met the McDonald 2005 criteria. The specific 
diagnostic sub-criterion met is represented in FAORRES/FAREST.  
 
famh.xpt 
Row STUDYID DOMAIN  USUBJID  FASEQ  FALNKID  FATESTCD  FATEST  FAOBJ 
1  ABC123  FAMH  MS01-120  1  1  DXCRITMT  Diagnostic Criteria Met  Relapsing Remitting Multiple Sclerosis 
2  ABC123  FAMH  MS01-130  1  1  DXCRITMT  Diagnostic Criteria Met  Secondary Progressive Multiple Sclerosis 
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famh.xpt 
Row  FAORRES  FAREST  FARESTNM  FARESTVR 
1 (cont) 
Greater than or equal to 2 attacks; objective clinical 
evidence of greater than or equal to 2 lesions or objective 
clinical evidence of 1 lesion with reasonable historical 
evidence of a prior attack  
Greater than or equal to 2 attacks; objective clinical evidence 
of greater than or equal to 2 lesions or objective clinical 
evidence of 1 lesion with reasonable historical evidence of a 
prior attack 
MCDONALD  2010 
2 (cont) 1 attack; 2 or more objective clinical lesions; Dissemination 
in time, demonstrated by MRI or second clinical attack 
1 attack; 2 or more objective clinical lesions; Dissemination 
in time, demonstrated by MRI or second clinical attack  MCDONALD  2005 
 
2.2 Relapse 
Progression of MS following the initial event is highly variable. However, clinical, functional, and imaging characteristics of the initial event, as well as the 
timing of relapses, have prognostic implications related to future progression and disability. A relapse is defined as new symptoms appearing, or existing 
symptoms worsening, after at least a month of stability, and lasting for at least 24 hours, but then stabilizing or resolving, either partially or completely. Relapses 
vary in both presentation and severity. For example, a new attack of optic neuritis represents a relapse while in other cases a relapse may cause debilitating motor 
or sensory symptoms.  There is no single, specific set of criteria for defining relapse, and investigators may define their own protocol criteria. MRI scans at 
relapse may show either new lesions or fresh activity in old lesions. When new symptoms fail to resolve and continually worsen, the condition is characterized as 
“progressive.” The frequency of relapses is thought to reflect a worsening of disease. Thus, relapse rates are an important endpoint in MS clinical studies. Given 
the potential for definitions of relapse to vary, defining and recording relapse criteria and making these data available to analysts is important.  The examples in 
this section show how to represent and relate relapses and their associated criteria. 
 
 
Figure 2.2: Concept Map of MS Relapse 
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2.2.1 Examples for Relapse 
 
The example below uses domains and variables which are not final at the time of the publication of this document. For additional assumptions, see Section 4. 
 
Example 1 
When a subject has a diagnosis of MS with potential for relapse, it is important to capture the criteria used to define relapse events. In this example, the subject 
was enrolled in the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study which focuses on RRMS. Relapse 
has only been defined in the protocol at the study level, and clinical presentation of relapse at the subject-level has not been collected. The primary diagnosis of 
RRMS is represented in MH while the relapse event is represented in CE. These events should be linked to each other using MHLNKID and CELNKID. The 
trial-level protocol defined relapse criteria are represented in the TS domain. If subject-level data were available and varied across subjects, they should be stored 
in the FACE domain (FATESTCD = “RLCRITMT, FATEST = “Relapse Criteria Met”) following the FAMH structure shown in Example 2 of Section 2.1.1, 
Examples for Medical History and Disease Course.  
 
Row 1:  Shows that the subject was diagnosed with RRMS in 1999. 
 
mh.xpt 
Row STUDYID DOMAIN USUBJID  MHSEQ MHLNKID  MHTERM  MHDECOD  MHCAT  MHSCAT  MHSTDTC 
1  ABC123  MH  MS01-104  1  1  RRMS  Relapsing Remitting Multiple Sclerosis  PRIMARY DIAGNOSIS  ONSET COURSE  1999-03 
 
Row 1:  Shows that the subject had a relapse event in 2012 of moderate severity as defined by the FREEDOMS study protocol (1 point increase on the 
EDSS (Expanded Disability Status Scale), data not shown).  
Row 2:  Shows that the subject had another relapse event in 2013 of mild severity as defined by the FREEDOMS study protocol (0.5 point increase on 
the EDSS, data not shown).  
 
ce.xpt 
Row STUDYID DOMAIN  USUBJID  CESEQ  CELNKID  CETERM  CESEV  CESTDTC  CEENDTC 
1  ABC123  CE  MS01-104  1  1  Multiple Sclerosis Relapse  MODERATE  2012-05-13  2012-05-29 
2  ABC123  CE  MS01-104  2  1  Multiple Sclerosis Relapse  MILD  2013-08-01  2013-08-04 
 
Row 1:  Shows how to represent data about how relapse criteria were defined at the trial level. 
Row 2:   Shows how to represent data about how severity criteria were defined at the trial level.   
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ts.xpt 
Row  STUDYID  DOMAIN  TSSEQ  TSPARMCD  TSPARM  TSVAL  TSVAL1  TSVAL2 
1  ABC123  TS  1  RLPSCRIT  Relapse 
Criteria 
Appearance of a new neurologic 
abnormality or the worsening of a pre-
existing neurologic abnormality that was 
previously stable or improving, at least 30 
days after onset of a preceding clinical  
demyelinating event, present for at least 24 
hours, and occurring in the absence of fever 
or infection. Confirmation was made by an 
independent rater and had to be accompanied 
by an increase of at 
least half a step (0.5) on the EDSS, 1 
point on 2 different function systems 
(FSs) of the EDSS, or 2 points on 1 FS 
(excluding the bowel/bladder or 
cerebral FS) 
2  ABC123  TS  2  SEVCRIT  Severity 
Criteria 
Mild severity is defined as a 0.5 point 
EDSS increase. Moderate severity is 
defined as a 1 to 2 point EDSS increase. 
Severe severity is defined as a greater than 
a 2 point EDSS increase. 
   
 
The relationship between the diagnosis of MS and the relapse events are represented in the RELREC table below. 
 
Rows 1-2:  Link the diagnosis of MS and the relapse events. This indicates that the MHLNKID variable for a diagnosis of RRMS is linked to potentially 
several relapse event records via the same value in the CELNKID variable.  
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  MH    MHLNKID    ONE  3 
2  ABC123  CE    CELNKID    MANY  3 
 
3  Disease Assessments 
3.1 Visual Acuity and Contrast Sensitivity 
Visual deterioration affects as many as 80% of patients with MS. It may be the first symptom noticed by a patient, contributing to disability and a diminished 
quality of life. Visual acuity is commonly tested for both near (14 inches) and distance (20 feet) vision. Following an episode of optic neuritis, a patient may 
recover both near and distance vision, but still have impaired low-contrast and color vision as well as visual-field losses.    
 
A common measure of high-contrast visual acuity, the Early Treatment Diabetic Retinopathy Study (ETDRS) chart determines the smallest black letters on a 
white background that can be distinguished from a distance of 3.2 meters. However, high-contrast tests lack sufficient sensitivity for many patients with MS. 
Therefore, the preferred test of vision for MS patients is the Low-Contrast Sloan Letter Charts (LCSLC), which uses a five-letter per line format of gray letters on 
a white background, with seven contrast levels ranging from high to low (100% to 0.6%).  Each chart is scored separately to determine contrast visual acuity. 
 
Another measure, The Pelli-Robson chart, measures contrast sensitivity as opposed to visual acuity (i.e., the ability to distinguish an object against backgrounds 
of different contrast levels).  Scores for both low-contrast letter acuity (Sloan) and contrast sensitivity (Pelli-Robson) have been shown to correlate with thinning 
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of the retinal nerve fiber layer (RNFL) determined using OCT, as well as with other measures of neurodegeneration. The Pelli-Robson measure has also been 
shown to be sensitive enough to detect treatment effects.  
 
When a patient has reduced visual acuity, a refraction test may be performed using a phoropter to determine the amount of ocular refractive error. This test 
generates a series of values that correspond to the degree of the subject’s refractive error, commonly sphere, cylinder, and axis. The sphere indicates how 
nearsighted (negative number) or farsighted (positive number) the patient is. The cylinder describes the curvature needed for the lens prescription to help correct 
irregularity in the curvature of the eye (astigmatism). The axis represents the orientation of the astigmatism and can range from 1 to 180 degrees. 
3.1.1 Examples for Visual Acuity and Contrast Sensitivity 
The examples below use domains and variables which are not final at the time of the publication of this document. For additional assumptions, see Section 4. 
 
The OE domain is for findings related to tests that measure a person's ocular health and visual status, to detect abnormalities in the components of the visual 
system, and to determine how well the person can see. 
 
Example 1 
This example shows how to represent results from both visual acuity and contrast sensitivity scales in the OE domain from one subject at one visit. OECAT and 
OESCAT should be used to differentiate between visual acuity scales, contrast sensitivity scales, and other ophthalmic exams stored in OE. The type of eye chart 
used during testing should be represented in OEMETHOD. If needed, the distance between the subject and chart should be represented in OETSTDTL.  
 
Rows 1-3:  Show the number of letters correctly identified at 3.2 meters during visual acuity testing using a high-contrast Early Treatment Diabetic 
Retinopathy Study (ETDRS) eye chart. Each eye is tested separately and then both eyes are tested together.  
Rows 4-6:  Show the number of letters correctly identified at 2 meters during visual acuity testing using a Low-Contrast Sloan Letter Chart with a contrast 
level of 2.5%. Each eye is tested separately and then both eyes are tested together.  
Rows 7-9:  Show the number of letters correctly identified at 2 meters during visual acuity testing using a Low-Contrast Sloan Letter Chart with a contrast 
level of 1.25%. Each eye is tested separately and then both eyes are tested together.  
Rows 10-12:  Show the Pelli-Robson contrast sensitivity log score. Each eye is tested separately and then both eyes are tested together.  
 
oe.xpt 
Row STUDYID DOMAIN USUBJID OESEQ OEGRPID  OETESTCD  OETEST  OETSTDTL  OECAT  OESCAT 
1  MS123  OE  MS01-01  1  1  NUMLCOR  Number of Letters Correct  Chart Distance 3.2 m  VISUAL ACUITY  HIGH CONTRAST 
2  MS123  OE  MS01-01  2  1  NUMLCOR  Number of Letters Correct  Chart Distance 3.2 m  VISUAL ACUITY  HIGH CONTRAST 
3  MS123  OE  MS01-01  3  1  NUMLCOR  Number of Letters Correct  Chart Distance 3.2 m  VISUAL ACUITY  HIGH CONTRAST 
4  MS123  OE  MS01-01  4  2  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
5  MS123  OE  MS01-01  5  2  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
6  MS123  OE  MS01-01  6  2  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
7  MS123  OE  MS01-01  7  3  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
8  MS123  OE  MS01-01  8  3  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
9  MS123  OE  MS01-01  9  3  NUMLCOR  Number of Letters Correct  Chart Distance 2 m  VISUAL ACUITY  LOW CONTRAST 
10  MS123  OE  MS01-01  10  4  LOGSCORE  Log Score    CONTRAST SENSITIVITY   
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Row STUDYID DOMAIN USUBJID OESEQ OEGRPID  OETESTCD  OETEST  OETSTDTL  OECAT  OESCAT 
11  MS123  OE  MS01-01  11  4  LOGSCORE  Log Score    CONTRAST SENSITIVITY   
12  MS123  OE  MS01-01  12  4  LOGSCORE  Log Score    CONTRAST SENSITIVITY   
 
oe.xpt 
Row  OEORRES  OESTRESC OESTRESN  OELOC  OELAT  OEMETHOD  OEDTC 
1 (cont)  60  60  60  EYE  RIGHT  ETDRS EYE CHART  2013-09-28 
2 (cont)  62  62  62  EYE  LEFT  ETDRS EYE CHART  2013-09-28 
3 (cont)  64  64  64  EYE  BILATERAL  ETDRS EYE CHART  2013-09-28 
4 (cont)  54  54  54  EYE  RIGHT  SLOAN LETTER EYE CHART 2.5%  2013-09-28 
5 (cont)  52  52  52  EYE  LEFT  SLOAN LETTER EYE CHART 2.5%  2013-09-28 
6 (cont)  56  56  56  EYE  BILATERAL  SLOAN LETTER EYE CHART 2.5%  2013-09-28 
7 (cont)  43  43  43  EYE  RIGHT  SLOAN LETTER EYE CHART 1.25%  2013-09-28 
8 (cont)  41  41  41  EYE  LEFT  SLOAN LETTER EYE CHART 1.25%  2013-09-28 
9 (cont)  45  45  45  EYE  BILATERAL  SLOAN LETTER EYE CHART 1.25%  2013-09-28 
10 (cont)  1.49  1.49  1.49  EYE  RIGHT  PELLI-ROBSON EYE CHART  2013-09-28 
11 (cont)  1.52  1.52  1.52  EYE  LEFT  PELLI-ROBSON EYE CHART  2013-09-28 
12 (cont)  1.65  1.65  1.65  EYE  BILATERAL  PELLI-ROBSON EYE CHART  2013-09-28 
 
Example 2 
This example shows how to represent results from a refraction test, which indicates the strength of the eyeglass prescription needed to be worn by the subject. 
Each component of the prescription should be listed in a separate OETESTCD/OETEST with an OECAT = “VISUAL ACUITY” and an OESCAT = 
“REFRACTION”.  
 
Rows 1-3:  Show the prescription for the subject’s right eye. The subject’s right eye had 5 diopters of myopia (OETEST = “Sphere”), 0.05 diopters of 
astigmatism (OETEST = “Cylinder”), with an axis of 172 (OETEST = “Axis”). 
Rows 4-6:  Show the prescription for the subject’s left eye. The subject’s left eye had 2.25 diopters of myopia (OETEST = “Sphere”), 1.25 diopters of 
astigmatism (OETEST = “Cylinder”), with an axis of 178 (OETEST = “Axis”). 
 
oe.xpt 
Row STUDYID DOMAIN USUBJID OESEQ OETESTCD  OETEST  OECAT  OESCAT  OEORRES  OEORRESU 
1  MS123  OE  MS01-01  13  SPHERE  Sphere  VISUAL ACUITY  REFRACTION  -5.00  DIOPTER 
2  MS123  OE  MS01-01  14  CYLINDER  Cylinder  VISUAL ACUITY  REFRACTION  -0.05  DIOPTER 
3  MS123  OE  MS01-01  15  AXIS  Axis  VISUAL ACUITY  REFRACTION  172  deg 
4  MS123  OE  MS01-01  16  SPHERE  Sphere  VISUAL ACUITY  REFRACTION  -2.25  DIOPTER 
5  MS123  OE  MS01-01  17  CYLINDER  Cylinder  VISUAL ACUITY  REFRACTION  -1.25  DIOPTER 
6  MS123  OE  MS01-01  18  AXIS  Axis  VISUAL ACUITY  REFRACTION  178  deg 
 
Row  OESTRESC OESTRESN OESTRESU  OELOC  OELAT  OEMETHOD  OEDTC 
1 (cont)  -5.00  -5.00  DIOPTER  EYE  RIGHT  PHOROPTER  2013-09-28 
2 (cont)  -0.05  -0.05  DIOPTER  EYE  RIGHT  PHOROPTER  2013-09-28 
3 (cont)  172  172  deg  EYE  RIGHT  PHOROPTER  2013-09-28 
4 (cont)  -2.25  -2.25  DIOPTER  EYE  LEFT  PHOROPTER  2013-09-28 
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Row  OESTRESC OESTRESN OESTRESU  OELOC  OELAT  OEMETHOD  OEDTC 
5 (cont)  -1.25  -1.25  DIOPTER  EYE  LEFT  PHOROPTER  2013-09-28 
6 (cont)  178  178  deg  EYE  LEFT  PHOROPTER  2013-09-28 
 
3.2 Imaging 
Various imaging techniques are valuable in the diagnosis and characterization of MS, including MRI and OCT. While MRI is out of scope for this version of the 
user guide, it may be included in a future version. 
 
3.2.1 Optical Coherence Tomography 
OCT is a valuable tool for assessing imaging biomarkers in MS. The following subsection describes OCT at a high level, with an emphasis on the data that are 
generated, and how they should be represented in SDTM. OCT is a relatively new imaging test that is used to assess integrity of first-order sensory neurons and 
unmyelinated axons in the retina, providing a unique noninvasive way to image the CNS. OCT has been used to assess axonal loss in optic neuritis, a common 
and often the first manifestation of MS. Since axonal degeneration has been linked to disability in MS, OCT may be useful as a biomarker to track progression 
and monitor treatment efficacy in clinical trials. OCT can be performed in about 10-15 minutes in office-based settings. Patients undergoing OCT sit in front of 
the instrument with their chin resting on a support and their forehead leaning against another support to keep it still. Each eye is tested separately. The instrument 
shines a low-intensity light into the eye without touching it.  
 
OCT uses a near-infrared optical beam to create a cross-sectional image of the retina with infrared light. A detector measures the degree of interference caused by 
the retina and then translates this into a high-resolution cross-sectional image. Two areas of the retina are generally imaged: the peripapillary region (around the 
optic nerve head/blind spot) and the macula (area of central vision). In patients with MS, OCT is used to show thinning of the innermost layer of the retina called 
the peripapillary RNFL, which reflects axonal degeneration, and a decrease in macular volume, where the most retinal ganglion cells are centered. The OCT scan 
quantifies both average RNFL thickness around the optic disc as well as RNFL thickness in different quadrants of the retina (temporal, superior, nasal, and 
inferior), which receive information from different parts of the visual field.  
 
In a normal eye, the RNFL is thickest in the superior and inferior quadrants of the retina compared to the nasal and temporal regions. Patients with MS typically 
have RNFL thinning across all quadrants, with even greater thinning in the temporal and nasal quadrants, compared to the superior and inferior quadrants. RNFL 
thinning occurs in MS patients regardless of whether they have experienced bouts of optic neuritis and worsens over time. Moreover, the degree of RNFL 
thinning correlates with visual loss and brain atrophy; and the pattern of RNFL thinning may, in the future, allow categorization of patients into various subtypes.  
 
There are two commercially available OCT technologies. Time domain OCT (brand name Zeiss Stratus) was historically the first technology available, used in 
some legacy trials. However, in recent years a newer technology called spectral domain OCT (currently available brand names Zeiss Cirrus and Heidelberg 
Spectralis) has become available, which has the advantage of higher resolution and faster scanning speed. Measurements from time domain and spectral domain 
technologies are not interchangeable. Average RNFL thickness measurements from the Cirrus and Spectralis spectral domain instruments may be combinable in 
the setting of a clinical trial.   
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Figure 3.2.1: Sample Output from OCT Imaging. 
The panel on the left shows a continuous measurement of RNFL thickness across each eye. These measurements are 
then averaged into four quadrants (temporal, nasal, superior, and inferior), which are evaluated for RNFL thickness. 
(Frohman, et al: Optical coherence tomography in multiple sclerosis, The Lancet Neurology 2006, 5:853-863)6. 
 
3.2.1.1  Examples for Optical Coherence Tomography Imaging 
For additional assumptions, see Section 4. 
 
Example 1 
RNFL thickness measurements and interpretation are represented in the Morphology (MO) domain. This example shows how to represent average RNFL 
thickness measurements determined by an OCT image from one subject at one visit. Average thickness is measured in each of the four quadrants (superior, nasal, 
inferior, and temporal) of both the left and right eyes. Additionally, an average thickness over all four quadrants is calculated. MOTSTDTL represents whether 
the average thickness result is the overall average or the quadrant average. Information about signal strength (an indication of the quality of the image produced) 
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is stored in SUPPMO and linked to the parent domain via MOGRPID. Information about the OCT device should be stored in the appropriate device domain. The 
Procedures (PR) domain may be used if information about the OCT procedure (e.g. start and end time of the image acquisition) needs to be represented.  
 
Rows 1-2:  Show the average RNFL thickness of the superior quadrant in the right and left eye. 
Rows 3-4:  Show the average RNFL thickness of the nasal quadrant in the right and left eye.  
Rows 5-6:  Show the average RNFL thickness of the inferior quadrant in the right and left eye.  
Rows 7-8:  Show the average RNFL thickness of the temporal quadrant in the right and left eye.  
Rows 9-10:  Show the average RNFL thickness over all four quadrants in the right and left eye, which is derived from each quadrant average.  
 
mo.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID  MOSEQ MOGRPID  MOTESTCD  MOTEST  MOTSTDTL  MOORRES MOORRESU MOSTRESC  MOSTRESN 
1  MS123  MO  MS01-01  345  1  1  AVGTHICK  Average Thickness  Intra-quadrant  90.9  um  90.9  90.9 
2  MS123  MO  MS01-01  345  2  2  AVGTHICK  Average Thickness  Intra-quadrant  91.6  um  91.6  91.6 
3  MS123  MO  MS01-01  345  3  1  AVGTHICK  Average Thickness  Intra-quadrant  92.7  um  92.7  92.7 
4  MS123  MO  MS01-01  345  4  2  AVGTHICK  Average Thickness  Intra-quadrant  91.5  um  91.5  91.5 
5  MS123  MO  MS01-01  345  5  1  AVGTHICK  Average Thickness  Intra-quadrant  90.3  um  90.3  90.3 
6  MS123  MO  MS01-01  345  6  2  AVGTHICK  Average Thickness  Intra-quadrant  93.1  um  93.1  93.1 
7  MS123  MO  MS01-01  345  7  1  AVGTHICK  Average Thickness  Intra-quadrant  92.3  um  92.3  92.3 
8  MS123  MO  MS01-01  345  8  2  AVGTHICK  Average Thickness  Intra-quadrant  93.3  um  93.3  93.3 
9  MS123  MO  MS01-01  345  9  1  AVGTHICK  Average Thickness  All Quadrants      91.6  91.6 
10  MS123  MO  MS01-01  345  10  2  AVGTHICK  Average Thickness  All Quadrants      92.4  92.4 
 
Row  MOSTRESU  MOLOC  MOLAT  MODIR  MOMETHOD  MODRVFL  MODTC 
1 (cont)  um  RETINAL NERVE FIBER LAYER  RIGHT  SUPERIOR  OCT    2011-02-08 
2 (cont)  um  RETINAL NERVE FIBER LAYER  LEFT  SUPERIOR   OCT    2011-02-08 
3 (cont)  um  RETINAL NERVE FIBER LAYER  RIGHT  NASAL   OCT    2011-02-08 
4 (cont)  um  RETINAL NERVE FIBER LAYER  LEFT  NASAL   OCT    2011-02-08 
5 (cont)  um  RETINAL NERVE FIBER LAYER  RIGHT  INFERIOR   OCT    2011-02-08 
6 (cont)  um  RETINAL NERVE FIBER LAYER  LEFT  INFERIOR   OCT    2011-02-08 
7 (cont)  um  RETINAL NERVE FIBER LAYER  RIGHT  TEMPORAL   OCT    2011-02-08 
8 (cont)  um  RETINAL NERVE FIBER LAYER  LEFT  TEMPORAL   OCT    2011-02-08 
9 (cont)  um  RETINAL NERVE FIBER LAYER  RIGHT     OCT  Y  2011-02-08 
10 (cont)  um  RETINAL NERVE FIBER LAYER  LEFT     OCT  Y  2011-02-08 
The signal strength reported by the OCT assessment for each eye is represented in the SUPPMO domain. 
 
Rows 1-2:  Show the signal strength of the OCT images from the right and left eye and links them to the thickness measurements in the parent domain via 
MOGRPID.  
 
suppmo.xpt 
Row STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  MS123  MO  MS01-01  MOGRPID  1  SIGSRNTH  Signal Strength  8 
2  MS123  MO  MS01-01  MOGRPID  2  SIGSRNTH  Signal Strength  9 
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Identifying information about the OCT device is represented in the Device Identifiers (DI) domain. Since SPDEVID is included as a variable in the other 
datasets, RELREC is not needed to relate DI to other domains. 
 
Rows 1-3:  Show the type, the manufacturer, and the serial number of the device used.  
 
di.xpt 
Row STUDYID DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  MS123  DI  345  1  TYPE  Device Type  OCT 
2  MS123  DI  345  2  MANUF  Manufacturer  ZEISS CIRRUS 
3  MS123  DI  345  3  SERIAL  Serial Number  TRE367 
 
3.3 Visual Evoked Potential 
Evoked potential tests measure the brain’s electrical activity when stimulated by different types of sensory input. Since demyelination of nerves in MS results in 
impaired nerve transmission, there may be a delay in how long it takes for the electrical impulse to reach the brain, as well as a dampening of the size of the 
response.  Of the various types of evoked potential testing, visual evoked potential (VEP) tests, which assess the integrity of the visual pathway, are most 
commonly used in the diagnosis and characterization of MS. This is in part because the visual pathway is often affected in the early stages of disease, even when 
patients are not aware of visual disturbances. VEP is thought to be one of the most sensitive tools for diagnosing optic neuritis, which is often the first sign of 
MS. 
 
To conduct VEP testing, electrodes are placed on the scalp to record electrical activity from the visual cortex in the brain. Subjects sit facing a screen on which a 
checkerboard pattern is displayed that reverses every half second. By patching one eye at a time, recordings are made of the visual pathway from each eye.   
 
VEP waveforms can be extracted from the electroencephalogram (EEG). The normal response pattern shows three peaks – a negative component with peak 
latency (delay) of about 75 msec (N75) after the pattern reversal, a positive peak with latency of about 100 msec (P100), and another negative peak at about 145 
msec (N145).  These peaks represent activity in different parts of the brain. In patients with MS, an eye that has been affected by optic neuritis will typically 
show a delay in the P100 peak.  
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Figure 3.3-1: Concept Map of Visual Evoked Potential (VEP) Assessment 
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Figure 3.3-2: Sample Output from VEP Assessment. 
Image reproduced with the permission of Donnell Creel (http://webvision.med.utah.edu/book/electrophysiology/visually-evoked-potentials/)7. 
3.3.1 Examples for Visual Evoked Potential 
The examples below use domains and variables which are not final at the time of the publication of this document. For additional assumptions, see Section 4. 
 
The following examples show how to represent components of a pattern-reversal VEP test elicited by checkerboard stimuli from a subject with optic neuritis in 
the Nervous Systems Findings (NV) domain. The NV domain for physiological findings related to the nervous system, including the brain, spinal cord, the 
cranial and spinal nerves, autonomic ganglia and plexuses. VEPs are detected via an EEG using leads that are placed on the back of the subject’s head. It is 
important to note that the nature of VEP testing is such that NVMETHOD should be equal to “EEG”, and that NVCAT should be equal to “VISUAL EVOKED 
POTENTIAL”. Several latencies from each eye including N75, P100, and N145 as well as the P100 peak to peak amplitude (75-100) are collected and should be 
represented in NVTESTCD/NVTEST. Details about the VEP equipment, including the checkerboard size, should be represented in the appropriate device 
domains. To interpret, each VEP component is compared against normative values established by the laboratory using healthy controls. In this example, a VEP 
component is considered abnormal if it falls outside of 3 standard deviations from the normative lab mean. These low and high values are stored in NVORNRLO 
and NVORNRHI, respectively, and the interpretation of each VEP component is represented in NVNRIND. In addition to interpreting each VEP component as 
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normal or abnormal, the overall test for each eye may have an interpretation. In this scenario, NVTESTCD/NVTEST should be equal to “INTP”/”Interpretation” 
and NVORRES should represent whether the overall test in each eye is normal or abnormal. NVGRPID links each VEP component to the overall interpretation.  
 
Example 1 
The NV domain should be used to represent the VEP latencies, P100 peak to peak amplitude, and their interpretations. SPDEVID allows the results to be 
connected to both the VEP testing device as well as the checkerboard size. 
 
Rows 1-4:  Show the VEP measurements from the right eye. 
Row 5:  Shows that when all the components of the right eye VEP are considered together, the overall test is interpreted as abnormal. 
Rows 6-9:  Show the VEP measurements from the left eye. 
Row 10:  Shows that when all the components of the left eye VEP are considered together, the overall test is interpreted as abnormal. 
 
nv.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID  NVSEQ NVGRPID  NVTESTCD  NVTEST  NVCAT  NVORRES  NVORRESU 
1  MS123  NV  MS01-01  123  1  1  N75LAT  N75 Latency  VISUAL EVOKED POTENTIAL  79.8  ms 
2  MS123  NV  MS01-01  123  2  1  P100LAT  P100 Latency  VISUAL EVOKED POTENTIAL  129  ms 
3  MS123  NV  MS01-01  123  3  1  N145LAT  N145 Latency  VISUAL EVOKED POTENTIAL  181  ms 
4  MS123  NV  MS01-01  123  4  1  P100AMP  P100 Amplitude  VISUAL EVOKED POTENTIAL  5.02  uV 
5  MS123  NV  MS01-01  123  5  1  INTP  Interpretation  VISUAL EVOKED POTENTIAL ABNORMAL   
6  MS123  NV  MS01-01  123  6  2  N75LAT  N75 Latency  VISUAL EVOKED POTENTIAL  83.8  ms 
7  MS123  NV  MS01-01  123  7  2  P100LAT  P100 Latency  VISUAL EVOKED POTENTIAL  126  ms 
8  MS123  NV  MS01-01  123  8  2  N145LAT  N145 Latency  VISUAL EVOKED POTENTIAL  160  ms 
9  MS123  NV  MS01-01  123  9  2  P100AMP  P100 Amplitude  VISUAL EVOKED POTENTIAL  4.37  uV 
10  MS123  NV  MS01-01  123  10  2  INTP  Interpretation  VISUAL EVOKED POTENTIAL ABNORMAL   
 
Row  NVSTRESC  NVSTRESN  NVSTRESU  NVORNRLO  NVORNRHI  NVNRIND  NVLOC  NVLAT  NVMETHOD  NVDTC 
1 (cont)  79.8  79.8  ms  54.68  94  NORMAL  EYE  RIGHT  EEG  2013-02-08 
2 (cont)  129  129  ms  76.75  113.71  ABNORMAL  EYE  RIGHT  EEG  2013-02-08 
3 (cont)  181  181  ms  114.27  156.03  ABNORMAL  EYE  RIGHT  EEG  2013-02-08 
4 (cont)  5.02  5.02  uV  5.26  12.64  ABNORMAL  EYE  RIGHT  EEG  2013-02-08 
5 (cont)  ABNORMAL            EYE  RIGHT  EEG  2013-02-08 
6 (cont)  83.8  83.8  ms  54.42  95.1  NORMAL  EYE  LEFT  EEG  2013-02-08 
7 (cont)  126  126  ms  76.9  115.78  ABNORMAL  EYE  LEFT  EEG  2013-02-08 
8 (cont)  160  160  ms  115.65  157.65  ABNORMAL  EYE  LEFT  EEG  2013-02-08 
9 (cont)  4.37  4.37  uV  4.78  12.7  ABNORMAL  EYE  LEFT  EEG  2013-02-08 
10 (cont) ABNORMAL            EYE  LEFT  EEG  2013-02-08 
 
Identifying information about the VEP device is represented in the Device Identifiers (DI) domain. 
 
Row 1:  Shows how to represent the VEP testing device as a device type. SPDEVID allows the device to be connected to both the testing device 
properties as well as the results generated. 
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di.xpt 
Row STUDYID DOMAIN SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  MS123  DI  123  1  TYPE  Device Type  VEP Testing Device 
 
Properties of the VEP device that may change between assessments are represented in the Device In-Use (DU) domain. 
 
Row 1:  Shows how to represent the checkerboard stimuli size in the DU domain. SPDEVID allows the checkerboard size to be connected to both the 
VEP testing device as well as the results generated. 
 
du.xpt 
Row STUDYID DOMAIN  USUBJID  SPDEVID  DUSEQ  DUTESTCD  DUTEST  DUORRES 
1  MS123  DU  MS01-01  123  1  CHCKSIZE  Checkerboard Size  32X32 
 
3.4 Functional Tests and Questionnaires  
Cognitive and functional impairments are the most clinically relevant and disabling symptoms of MS and may be tested via clinician-administered cognitive, 
functional, or patient-reported assessments. A number of these assessments are available and are used both clinically and in clinical trials. These assessments are 
maintained as standalone guides on the CDISC website at http://www.cdisc.org/ft-and-qs. In MS, the EDSS is the most widely used measure to score the level of 
impairment. Another commonly used assessment is the Multiple Sclerosis Functional Composite (MSFC), which assesses functional impairments in ambulation, 
dexterity, and mental processing speed.  
 
The table below lists the cognitive and functional assessments that have been or will be implemented in either a Questionnaire or Functional Test Supplement to 
the SDTMIG. Sponsors should refer to the link above if a scale of interest is not included below, as it may have been developed for another therapeutic area, and 
new scales are implemented in an ongoing basis by the CDISC QS and FT Terminology and Standards Development sub-teams. See CDISC COP 017, CDISC 
SDTMIG Questionnaire and Functional Test Supplements (http://www.cdisc.org/bylaws-and-policies) for details on implementing or requesting development of 
standard questionnaires for SDTM-based submissions. 
 
Full Name and Abbreviation  Domain 
Status of Permission 
to Develop Controlled 
Terminology 
Status of Controlled 
Terminology 
Status of Supplement 
Development 
Kurtzke Expanded Disability Status Scale (EDSS)  QS  Public Domain  Terminology Developed  Supplement Developed 
Kurtzke Functional Systems Scores (KFSS)  QS  Public Domain  Terminology Developed  Supplement Developed 
Bladder Control Scale (BLCS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Bowel Control Scale (BWCS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Impact of Visual Impairment Scale (IVIS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Modified Fatigue Impact Scale (MFIS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Multiple Sclerosis Quality of Life-54 (MSQOL-54)  QS  Permission Granted  Terminology Developed  Supplement Developed 
RAND 36-Item Health Survey 1.0 (RAND-36 V1.0)  QS  Permission Granted  Terminology Developed  Supplement Developed 
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Full Name and Abbreviation  Domain 
Status of Permission 
to Develop Controlled 
Terminology 
Status of Controlled 
Terminology 
Status of Supplement 
Development 
36-Item Short-Form Health Survey (SF-36)  QS  Under Discussion     
Disease Steps  QS  Public Domain  Terminology Developed  Supplement Developed 
Patient Determined Disease Steps (PDDS)  QS  Public Domain  Terminology Developed  Supplement Developed 
Functional Assessment of Multiple Sclerosis (FAMS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Fatigue Severity Scale (FSS)  QS  Permission Granted  Terminology Developed  Supplement Developed 
Visual Functioning Questionnaire – 25 (VFQ-25 
INTERVIEWER ADMINISTERED) Version 2000  QS  Permission Granted  Terminology Developed  Supplement Developed 
Visual Functioning Questionnaire – 25 (VFQ-25 SELF-
ADMINISTERED) Version 2000  QS  Permission Granted  Terminology Developed  Supplement Developed 
European Quality of Life Five Dimension Three Level Scale 
(EQ-5D-3L)  QS  Permission Granted  Terminology Developed  Supplement Developed 
European Quality of Life Five Dimension Five Level Scale 
(EQ-5D-5L)  QS  Permission Granted  Terminology Developed  Supplement Developed 
12-Item MS Walking Scale (MSWS-12)  QS  No Response      
Multiple Sclerosis Impact Scale Version 1 (MSIS-29 V1)   QS  No Response      
Multiple Sclerosis Impact Scale Version 2 (MSIS-29 V2)  QS  No Response      
Timed 25-Foot Walk (T25FW)  FT  Permission Granted  Terminology Developed  Supplement Developed 
Nine-Hole Peg Test (NHPT)  FT  Permission Granted  Terminology Developed  Supplement Developed 
Paced Auditory Serial Addition Test (PASAT)  FT  Permission Granted  Terminology Developed  Supplement Developed 
Symbol Digit Modalities Test (SDMT)  FT  Total Score Only – 
Permission not needed  Terminology in Development  NA 
Hauser Ambulation Index  FT  Permission Granted  Terminology Developed  Supplement  Developed 
Timed Up and Go (TUG)  FT  Public Domain  Terminology Developed  Supplement in Development 
6 Minute Walk Test (6MWT)  FT  Public Domain  Terminology Developed  Supplement in Development 
 
4  Additional Assumptions for Domains 
The domains used in this document operate under certain assumptions which may be found, with the domain specification tables, in the implementation guides to 
which they belong (e.g., the SDTMIG for domains pertaining to human clinical trials and the SDTMIG-MD for domains pertaining to the use of medical 
devices). All of the assumptions from those implementation guides apply for this user guide. The assumptions given below apply for MS clinical trials in 
addition to the standard assumptions.  
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4.1 Additional Assumptions for Medical History Domain Model 
1.  Valid terms for MHTERM include “MULTIPLE SCLEROSIS” and all subtypes based on disease course (e.g., RELAPSING REMITTING MULTIPLE 
SCLEROSIS or RRMS). These terms should be represented in MHTERM when MHCAT=“PRIMARY DIAGNOSIS”. Coding to the preferred term 
with MedDRA for multiple sclerosis to populate MHDECOD is optional but encouraged.  
2.  In the case where the subject’s current course of disease has not changed from the onset course, a record for current course is not added. The relative 
timing variable, MHENRTPT should be used to indicate that the onset course is “ONGOING” at the date of evaluation (MHSTTPT). 
3.  If general medical history information is also captured either as verbatim text or pre-specified text, it can be coded with MedDRA and the Preferred 
Term reported in MHDECOD based on the sponsor’s coding criteria for medical history. 
4.  Terminology: 
1.  The terminology for MHCAT includes “PRIMARY DIAGNOSIS” and “GENERAL”. Note that MHCAT is not subject to controlled 
terminology, and this is just a suggestion. 
2.  Where collected, initial symptoms for multiple sclerosis should be mapped to a separate MHTERM with a MHCAT of “PRIMARY 
DIAGNOSIS” and a MHSCAT of “INITIAL SYMPTOMS”.  
4.2 Additional Assumptions for Ophthalmic Examinations Domain Model 
1.  OECAT should be used to differentiate between assessments of visual acuity and contrast sensitivity. The specific eye chart used should be represented 
in OEMETHOD. 
2.  Chart reading distance should be represented in OETSTDTL. 
4.3 Additional Assumptions for Morphology Domain Model 
1.  A general MOTEST name of “Average Thickness” should be used for RNFL assessment via OCT. MOTSTDTL should be used to represent whether 
the thickness result pertains to a single-quadrant average thickness or an average across all quadrants. 
4.4 Additional Assumptions for Nervous System Findings Domain Model 
1.  Visual Evoked Potential (VEP) should be represented in NVCAT, not NVMETHOD, and the details as to which peak latency (or peak-to-peak 
amplitude) is being recorded should be represented in NVTESTCD/NVTEST as they represent the individual components of the VEP test. VEP 
assessment is a form of EEG, which is what should be represented in NVMETHOD. 
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Appendices 
Appendix A: Work Group 
Core Development Team 
Name  Institution/Organization 
Bess LeRoy  Critical Path Institute 
Jon Neville  Critical Path Institute 
Steve Kopko  CDISC 
Christina Casteris  Biogen Idec 
Nate Friemark  Theorem Clinical 
Beverly Mersing  SDC Clinical 
Donna Sattler  MaxisIT 
 
Clinical Science and Technical Subject Matter Experts 
Name  Institution/Organization 
Ellen Mowry  Johns Hopkins  
Peter Chin  Novartis 
Laura Balcer  New York University 
Rob Bermel  Cleveland Clinic Foundation 
Lauren Krupp  Stony Brook Medicine 
Myla Goldman  University of Virginia 
 
Terminology and Questionnaires/Functional Tests Supplement Development 
Name  Institution/Organization 
Bob Stafford  Critical Path Institute 
Emily Hartley  Critical Path Institute 
Bernice Yost  CDISC 
Erin Muhlbradt  NCI EVS 
Roberta Rosenberg  Pfizer 
Gary Cunningham   Teva 
Jordan Li  NCI EVS 
Donna Sattler  MaxisIT 
Fred Wood  Accenture 
Randall Austin  Glaxo-Smith Kline 
Christina Casteris  Biogen Idec 
Nate Friemark  Theorem Clinical 
Steve Kopko  CDISC 
Tom Guinter  Independent  
Lacey Wallace  Eli Lilly 
Linda Barrett  Eli Lilly 
 
Appendix B: Glossary and Abbreviations 
BRIDG  Biomedical Research Integrated Domain Group 
CDASH  Clinical Data Acquisition Standards Harmonization 
CDE  Common Data Element 
CDISC  Clinical Data Interchange Standards Consortium 
CFAST  Coalition for Accelerating Standards and Therapies 
CIS  Clinically Isolated Syndrome 
CNS  Central Nervous System 
C-Path  Critical Path Institute  
CRF  Case Report Form 
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Appendix B1: Supplemental Qualifiers Name Codes 
The following table contains additional standard QNAM and QLABEL values for use in the Supplemental 
Qualifiers (SUPP--) special-purpose datasets.  
 
QNAM  QLABEL  Applicable Domains 
SIGSRNTH  Signal Strength  MO 
Appendix C: References 
1.  Lublin FD, et al. Defining the clinical course of Multiple Sclerosis: the 2013 revisions.  Neurology, in 
press, 2014, May 28. 
2.  Lublin FD and Reingold SC. Defining the clinical course of multiple sclerosis: results of an international 
survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents 
in Multiple Sclerosis. Neurology. 1996; 46: 907-11. 
3.  McDonald WI, et al. (2001).  Recommended diagnostic criteria for multiple sclerosis: guidelines from the 
International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001; 50 (1): 121–7. 
4.  Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. 
Annals of neurology. 2005; 58: 840-846. 
5.  Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. 
Annals of neurology. 2011; 69: 292-302. 
6.  Frohman, et al. Optical coherence tomography in multiple sclerosis. The Lancet Neurology. 2006; 5:853-
863. 
7.  Creel, Donnell J. “Visually Evoked Potentials.” Webvision: The Organization of the Retina and Visual 
System. University of Utah. Web. 30 Oct. 2013.  
CSF  Cerebrospinal Fluid 
EEG  Electroencephalogram   
ETDRS  Early Treatment Diabetic Retinopathy Study 
FDA  Food and Drug Administration 
MRI  Magnetic Resonance Imaging 
MS  Multiple Sclerosis 
MSFC  Multiple Sclerosis Functional Composite 
MSOAC  Multiple Sclerosis Outcome Assessments Consortium  
NCI EVS  National Cancer Institute Enterprise Vocabulary Services 
NINDS  National Institute for Neurological Disorder and Stroke 
OCT  Optical Coherence Tomography 
OD  Oculus Dexter 
OS  Oculus Sinister 
OU  Oculus Uterque 
PPMS  Primary Progressive Multiple Sclerosis 
PRMS  Progressive Relapsing Multiple Sclerosis  
RNFL  Retinal Nerve Fiber Layer 
RRMS  Relapsing Remitting Multiple Sclerosis  
SDS  Submission Data Standards 
SDTM  Study Data Tabulation Model 
SDTMIG  Study Data Tabulation Model Implementation Guide for Human Clinical Trials 
SDTMIG-MD  Study Data Tabulation Model Implementation Guide for Medical Devices 
SME  Subject Matter Expert 
SPMS  Secondary Progressive Multiple Sclerosis 
SRC  Standards Review Council  
TAUG  Therapeutic Area User Guide 
TCB  TransCelerate BioPharma 
UML  Universal Modeling Language 
VEP  Visual Evoked Potential 
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Appendix D: Representations and Warranties, Limitations of 
Liability, and Disclaimers 
CDISC Patent Disclaimers 
It is possible that implementation of and compliance with this standard may require use of subject matter covered by 
patent rights. By publication of this standard, no position is taken with respect to the existence or validity of any 
claim or of any patent rights in connection therewith. CDISC, including the CDISC Board of Directors, shall not be 
responsible for identifying patent claims for which a license may be required in order to implement this standard or 
for conducting inquiries into the legal validity or scope of those patents or patent claims that are brought to its 
attention. 
 
Representations and Warranties 
“CDISC grants open public use of this User Guide (or Final Standards) under CDISC’s copyright.”  
 
Each Participant in the development of this standard shall be deemed to represent, warrant, and covenant, at the time 
of a Contribution by such Participant (or by its Representative), that to the best of its knowledge and ability: (a) it 
holds or has the right to grant all relevant licenses to any of its Contributions in all jurisdictions or territories in 
which it holds relevant intellectual property rights; (b) there are no limits to the Participant’s ability to make the 
grants, acknowledgments, and agreements herein; and (c) the Contribution does not subject any Contribution, Draft 
Standard, Final Standard, or implementations thereof, in whole or in part, to licensing obligations with additional 
restrictions or requirements inconsistent with those set forth in this Policy, or that would require any such 
Contribution, Final Standard, or implementation, in whole or in part, to be either: (i) disclosed or distributed in 
source code form; (ii) licensed for the purpose of making derivative works (other than as set forth in Section 4.2 of 
the CDISC Intellectual Property Policy (“the Policy”)); or (iii) distributed at no charge, except as set forth in 
Sections 3, 5.1, and 4.2 of the Policy. If a Participant has knowledge that a Contribution made by any Participant or 
any other party may subject any Contribution, Draft Standard, Final Standard, or implementation, in whole or in 
part, to one or more of the licensing obligations listed in Section 9.3, such Participant shall give prompt notice of the 
same to the CDISC President who shall promptly notify all Participants. 
 
No Other Warranties/Disclaimers. ALL PARTICIPANTS ACKNOWLEDGE THAT, EXCEPT AS PROVIDED 
UNDER SECTION 9.3 OF THE CDISC INTELLECTUAL PROPERTY POLICY, ALL DRAFT STANDARDS 
AND FINAL STANDARDS, AND ALL CONTRIBUTIONS TO FINAL STANDARDS AND DRAFT 
STANDARDS, ARE PROVIDED “AS IS” WITH NO WARRANTIES WHATSOEVER, WHETHER EXPRESS, 
IMPLIED, STATUTORY, OR OTHERWISE, AND THE PARTICIPANTS, REPRESENTATIVES, THE CDISC 
PRESIDENT, THE CDISC BOARD OF DIRECTORS, AND CDISC EXPRESSLY DISCLAIM ANY 
WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR ANY PARTICULAR OR 
INTENDED PURPOSE, OR ANY OTHER WARRANTY OTHERWISE ARISING OUT OF ANY PROPOSAL, 
FINAL STANDARDS OR DRAFT STANDARDS, OR CONTRIBUTION. 
 
Limitation of Liability 
IN NO EVENT WILL CDISC OR ANY OF ITS CONSTITUENT PARTS (INCLUDING, BUT NOT LIMITED 
TO, THE CDISC BOARD OF DIRECTORS, THE CDISC PRESIDENT, CDISC STAFF, AND CDISC 
MEMBERS) BE LIABLE TO ANY OTHER PERSON OR ENTITY FOR ANY LOSS OF PROFITS, LOSS OF 
USE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER 
UNDER CONTRACT, TORT, WARRANTY, OR OTHERWISE, ARISING IN ANY WAY OUT OF THIS 
POLICY OR ANY RELATED AGREEMENT, WHETHER OR NOT SUCH PARTY HAD ADVANCE NOTICE 
OF THE POSSIBILITY OF SUCH DAMAGES. 
 
Note: The CDISC Intellectual Property Policy can be found at  
http://www.cdisc.org/about/bylaws_pdfs/CDISCIPPolicy-FINAL.pdf. 
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6 Domain Models Based on the General 
Observation Classes 
6.3 Findings 
Nervous System Findings (NV) 
NV - Description/Overview for Nervous System Findings Domain Model 
A domain for physiological findings related to the nervous system, including the brain, spinal cord, the cranial and spinal nerves, autonomic ganglia and 
plexuses. 
 
The NV domain is still in the very early stages of development.  
NV - Specification for Nervous System Findings Domain Model 
nv.xpt, Nervous System Findings — Findings, Version 3.3. One record per Nervous System Findings finding per location per time point per visit per 
subject, Tabulation 
Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char  NV  Identifier  Two-character abbreviation for the domain.  Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all 
applications or submissions involving the product. 
Req 
NVSEQ  Sequence Number  Num     Identifier  Sequence Number given to ensure uniqueness of subject records 
within a domain. May be any valid number.  
Req 
NVGRPID  Group ID  Char     Identifier  Used to tie together a block of related records in a single domain for a 
subject. 
Perm 
NVREFID  Reference ID  Char     Identifier  Internal or external procedure identifier.   Perm 
NVSPID  Sponsor-Defined Identifier  Char    Identifier  Sponsor-defined reference number. Perhaps pre-printed on the CRF as 
an explicit line identifier or defined in the sponsor's operational 
database. Example: Line number from the procedure or test page. 
Perm 
NVLNKID  Link ID   Char    Identifier   Identifier used to link a procedure to the assessment results over the 
course of the study.  
Perm 
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Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVTESTCD  Test or Examination Short 
Name 
Char  *  Topic  Short name of the measurement, test, or examination described in 
NVTEST. It can be used as a column name when converting a dataset 
from a vertical to a horizontal format. The value in NVTESTCD 
cannot be longer than 8 characters, nor can it start with a number (e.g., 
“1TEST”). NVTESTCD cannot contain characters other than letters, 
numbers, or underscores. Example: SUVR 
Req 
NVTEST  Test or Examination Name  Char  *  Synonym 
Qualifier 
Verbatim name of the test or examination used to obtain the 
measurement or finding. The value in NVTEST cannot be longer than 
40 characters. Example: Standard Uptake Value Ratio, etc. 
 
Req 
NVCAT  Category for Test  Char  *  Grouping 
Qualifier 
Used to categorize observations across subjects.   Perm 
NVSCAT  Subcategory for Test  Char  *  Grouping 
Qualifier 
A further categorization.  Perm 
NVPOS  Position of Subject  Char  (POSITION)  Record 
Qualifier 
Position of the subject during a measurement or examination. 
Examples: SUPINE, STANDING, SITTING. 
Perm 
NVORRES  Result or Finding in Original 
Units 
Char    Result 
Qualifier 
Result of the procedure measurement or finding as originally received 
or collected.  
Exp 
NVORRESU  Original Units  Char  (UNIT)  Variable 
Qualifier  
Original units in which the data were collected. The unit for 
NVORRES.  
Perm 
NVSTRESC  Character Result/Finding in 
Std Format 
Char    Result 
Qualifier 
Contains the result value for all findings, copied or derived from 
NVORRES in a standard format or standard units. NVSTRESC 
should store all results or findings in character format; if results are 
numeric, they should also be stored in numeric format in NVSTRESN.  
Exp 
NVSTRESN  Numeric Result/Finding in 
Standard Units 
Num     Result 
Qualifier 
Used for continuous or numeric results or findings in standard format; 
copied in numeric format from NVSTRESC. NVSTRESN should 
store all numeric test results or findings. 
Perm 
NVSTRESU  Standard Units  Char  (UNIT)  Variable 
Qualifier 
Standardized unit used for NVSTRESC or NVSTRESN.   Perm 
NVSTAT  Completion Status  Char  (ND)  Record 
Qualifier 
Used to indicate a test was not done, or a measurement was not taken. 
Should be null if a result exists in NVORRES.  
Perm 
NVREASND  Reason Test Not Performed  Char     Record 
Qualifier 
Describes why a measurement or test was not performed. Examples: 
BROKEN EQUIPMENT or SUBJECT REFUSED. Used in 
conjunction with NVSTAT when value is NOT DONE. 
Perm 
NVXFN  Raw Data File 
 
Char     Record 
Qualifier 
Filename for an external file used to populate the NV domain.   Perm 
NVNAM  Laboratory/Vendor Name   Char    Record 
Qualifier 
Name or identifier of the vendor (e.g., laboratory) that provided the 
test results.  
 
Perm 
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Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVLOC  Location Used for 
Measurement 
Char  (LOC)  Record 
Qualifier 
  Perm 
NVLAT  Specimen Laterality within 
Subject 
Char  (LAT)  Variable 
Qualifier 
Qualifier for laterality of the specimen within the subject for paired 
specimens.  Examples: LEFT, RIGHT, BILATERAL. 
Perm 
NVDIR  Specimen Directionality 
within Subject 
Char  (DIR)  Variable 
Qualifier 
Qualifier for directionality of the specimen within the subject.  
Examples: DORSAL, PROXIMAL. 
Perm 
NVMETHOD  Method of Procedure Test   Char  (METHOD)  Record 
Qualifier 
Method of the procedure.  Perm 
NVBLFL  Baseline Flag  Char  (NY)  Record 
Qualifier 
Indicator used to identify a baseline value. The value should be “Y” or 
null. 
Exp 
NVDRVFL  Derived Flag  Char  (NY)  Record 
Qualifier 
Used to indicate a derived record. The value should be Y or null. Records 
which represent the average of other records, or that do not come from the 
CRF, or are not as originally collected or received are examples of records that 
would be derived for the submission datasets. If NVDRVFL=Y, then 
NVORRES would be null, with, and (if numeric) NVSTRESN having the 
derived value. 
Perm 
NVEVAL  Evaluator  Char  *  Record 
Qualifier 
Role of the person who provided the evaluation. Used only for results 
that are subjective (e.g., assigned by a person or a group). Should be 
null for records that contain collected or derived data. Examples: 
INVESTIGATOR, ADJUDICATION COMMITTEE, VENDOR. 
Perm 
VISITNUM  Visit Number  Num     Timing  1. Clinical encounter number.  
2. Numeric version of VISIT, used for sorting. 
Exp 
VISIT  Visit Name  Char     Timing  1. Protocol-defined description of clinical encounter.  
2. May be used in addition to VISITNUM and/or VISITDY.  
Perm 
VISITDY  Planned Study Day of Visit  Num     Timing  Planned study day of the visit based upon RFSTDTC in 
Demographics. 
Perm 
NVDTC  Date/Time of Test  Char  ISO 8601   Timing  Date of procedure or test.  Exp 
NVDY  Study Day of Test   Num     Timing  1. Study day of the procedure or test, measured as integer days.  
2. Algorithm for calculations must be relative to the sponsor-defined 
RFSTDTC variable in Demographics.  
Perm 
NVTPT  Planned Time Point Name  Char     Timing  1. Text Description of time when measurement should be taken.  
2. This may be represented as an elapsed time relative to a fixed 
reference point, such as time of last dose. See NVTPTNUM and 
NVTPTREF. Examples: Start, 5 min post. 
Perm 
NVTPTNUM  Planned Time Point Number  Num     Timing  Numerical version of NVTPT to aid in sorting.   Perm 
NVELTM  Planned Elapsed Time from 
Time Point Ref 
Char  ISO 8601  Timing  Planned elapsed time (in ISO 8601) relative to a fixed time point reference 
(NVTPTREF). Not a clock time or a date time variable. Represented as an 
ISO 8601 duration. Examples: “-PT15M” to represent the period of 15 
minutes prior to the reference point indicated by NVTPTREF, or “PT8H” 
to represent the period of 8 hours after the reference point indicated by 
NVTPTREF. 
Perm 
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Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVTPTREF  Time Point Reference   Char     Timing  Name of the fixed reference point referred to by NVELTM, 
NVTPTNUM, and NVTPT. Examples: PREVIOUS DOSE, 
PREVIOUS MEAL. 
Perm 
NVRFTDTC  Date/Time of Reference Time 
Point 
Char  ISO 8601  Timing  Date/time of the reference time point, NVTPTREF.  Perm 
* Indicates variable may be subject to controlled terminology (Parenthesis indicates CDISC/NCI codelist code value) 
NV - Assumptions for Nervous System Findings Domain Model 
1.  NV Definition: This domain has been designed to store data on neurological physiological findings that include information relating to the brain, the 
spinal cord, and the nerves. 
2.  Additional Findings Qualifiers 
a.  The following variables would not generally be used in NV: --LOINC, --FAST, --TOX, --TOXGR.  
NV - Examples for Nervous System Findings Domain Model 
 
Example 1 
This example shows measures for standard uptake value ratios taken from three PET scans. NVDTC corresponds to the date of the PET or PET/CT procedure 
from which these results were obtained. 
 
Rows 1-2:   Show the Standard Uptake Value Ratio (SUVR) findings based on a PET/CT scan for subject AD01-101.  
Rows 3-4:  Show the SUVR findings based on a PET/CT scan for subject AD01-102. 
Rows 5-6:  Show the SUVR findings based on an FDG-PET scan for subject AD AD01-103. 
 
nv.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  NVSEQ  NVREFID  NVLNKID  NVTESTCD  NVTEST  NVORRES  NVORRESU 
1  ABC123  NV  AD01-101  22  1  1236  03  SUVR  Standard Uptake Value Ratio  .95  RATIO 
2  ABC123  NV  AD01-101  22  2  1236  03  SUVR  Standard Uptake Value Ratio  1.17  RATIO 
3  ABC123  NV  AD01-102  22  1  1237  04  SUVR  Standard Uptake Value Ratio  1.21  RATIO 
4  ABC123  NV  AD01-102  22  2  1237  04  SUVR  Standard Uptake Value Ratio  1.78  RATIO 
5  ABC123  NV  AD01-103  44  1  1238  05  SUVR  Standard Uptake Value Ratio  1.52  RATIO 
6  ABC123  NV  AD01-103  44  2  1238  05  SUVR  Standard Uptake Value Ratio  1.63  RATIO 
 
Row  NVSTRESC  NVSTRESN  NVSTRRESU  NVLOC  NVDIR  NVMETHOD  NVDTC 
1 (cont)  .95  .95  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
2 (cont)  1.17  1.17  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
3 (cont)  1.21  1.21  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
4 (cont)  1.78  1.78  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
5 (cont)  1.52  1.52  RATIO  PRECUNEUS    FDGPET  2012-05-22 
6 (cont)  1.63  1.63  RATIO  CINGULATE CORTEX  POSTERIOR  FDGPET  2012-05-22 
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A supplemental qualifiers dataset is used for additional data elements that are not part of the NV domain. 
 
Rows 1-6:   Shows the reference region used for the SUVR tests shown in the NV domain.  
 
suppnv.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  ABC123  NV  AD01-101  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
2  ABC123  NV  AD01-101  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
3  ABC123  NV  AD01-102  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
4  ABC123  NV  AD01-102  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
5  ABC123  NV  AD01-103  NVSEQ  1  REFREG  Reference Region  PONS 
6  ABC123  NV  AD01-103  NVSEQ  2  REFREG  Reference Region  PONS 
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6 Domain Models Based on the General 
Observation Classes 
6.3 Findings 
Ophthalmic Examinations (OE) 
OE – Description/Overview for Ophthalmic Examinations Domain Model 
The OE domain is for findings related to tests that measure a person's ocular health and visual status, to detect abnormalities in the components of the visual 
system, and to determine how well the person can see. 
OE – Specification for Ophthalmic Examinations Domain Model 
oe.xpt, Ophthalmic Examinations — Findings, SDTM Version 3.3. One record per ophthalmic finding (as a combination of test and test details) per 
method per location, including its qualifiers laterality and directionality, per evaluator per time point per visit per subject, Tabulation 
Variable 
Name 
Variable Label  Type  Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char  OE  Identifier  Two-character abbreviation for the domain most relevant to the observation. The 
Domain abbreviation is also used as a prefix for variables to ensure uniqueness 
when datasets are merged.  
Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all applications 
or submissions involving the product.  
Req 
LOCID  Location Identifier  Char  *  Identifier  Used as a key identifying variable to store the terms “OD”, “OS” and “OU”. Refer 
to Assumption 3. 
Exp 
OESEQ  Sequence Number  Num     Identifier  Sequence number to ensure uniqueness of records within a dataset for a subject. 
May be any valid number (including decimals) and does not have to start at 1.  
Req 
OEREPNUM  Repetition Number  Num    Identifier  The chronological incidence number of a finding that is repeated within a given 
date/time for the same test.  The level of granularity can vary, for example, can be 
within a timepoint or within a visit.  Used for cases where date/time alone cannot 
distinguish between repetitions. 
 
OEGRPID  Group ID  Char     Identifier  Optional group identifier, used to link together a block of related records within a 
subject in a domain (Section 3.4). 
Perm 
© 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved   OE - Page 1 
Draft  May 01, 2014 SDTMIG Draft Domain: Ophthalmic Examinations (OE) 
Variable 
Name 
Variable Label  Type  Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
OELNKID  Link ID  Char    Identifier  Identifier used to link related records across domains. This may be a one-to-one or 
a one-to-many relationship. For Example: A single location and its qualifiers may 
have multiple measurements/assessments based on a procedure performed at a 
study visit and OELINKID used to link to the specific procedure performed. 
Perm 
OETESTCD  Short Name of 
Measurement, Test or 
Examination 
Char  (OETESTCD)  Topic  Short character value for OETEST used as a column name when converting a 
dataset from a vertical format to a horizontal format. The short value can be up to 8 
characters. Examples: NUMLCOR. 
Req 
OETEST  Name of Measurement, Test 
or Examination 
Char  (OETEST)  Synonym 
Qualifier 
Long name for test. Example: Number of Letters Correct for 
OETESTCD=NUMLCOR. 
The following rules must be considered when requesting additional terms for tests: 
•  OETESTCD and OETEST must have a 1:1 relationship. 
•  OETEST, OETSTDTL and OEMETHOD are expected to uniquely 
differentiate a test. 
o  Result and other variable’s values may have a different meaning 
depending on values of each unique test. It means that more 
granular Value Level Metadata (VLM) may need to be defined for 
appropriate interpretation of findings. 
Req 
OETSTDTL  Measurement, Test or 
Examination Detail 
Char  *  Variable 
Qualifier 
Further description of OETESTCD and OETEST.  Example: “Chart Distance 
3.2m” when OETESTCD = NUMLCOR. 
See Notes for OETEST. 
Perm 
OECAT  Category  Char  *  Grouping 
Qualifier 
Used to define a category of topic-variable values. Examples: VISUAL ACUITY, 
CONTRAST SENSITIVIY, OCULAR COMFORT. 
Not to be used as a test differentiator, just as a grouping variable. 
See Assumption 4. 
Perm 
OESCAT  Subcategory  Char  *  Grouping 
Qualifier 
Used to define a further categorization of OECAT values. Example: HIGH 
CONTRAST and LOW CONTRAST when OECAT is VISUAL ACUITY. 
Not to be used as a test differentiator, just as a sub-grouping variable. 
See Assumption 4. 
Perm 
OEORRES  Result or Finding in 
Original Units 
Char    Result 
Qualifier 
Result of the measurement or finding as originally received or collected. Examples: 
120, <1,NORMAL,  RED SPOT VISIBLE ON CONJUNCTIVA 
Exp 
OEORRESU  Original Units  Char  (UNIT)  Variable 
Qualifier 
Unit for OEORRES. Examples: IN, mm, um  Exp 
OEORNRLO  Normal Range Lower 
Limit-Original Units 
Char    Variable 
Qualifier 
Lower end of normal range or reference range for results stored in OEORRES.  Perm 
OEORNRHI  Normal Range Upper Limit-
Original Units 
Char    Variable 
Qualifier 
Upper end of normal range or reference range for results stored in OEORRES.  Perm 
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Variable 
Name 
Variable Label  Type  Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
OESTRESC  Result or Finding in 
Standard Format  
Char    Result 
Qualifier 
Contains the result value for all findings, copied or derived from OEORRES in a 
standard format or in standard units. OESTRESC should store all results or 
findings in character format; if results are numeric, they should also be stored in 
numeric format in OESTRESN. For example, if various tests have results 
“NONE”, “NEG”, and “NEGATIVE” in OEORRES and these results effectively 
have the same meaning, they could be represented in standard format in 
OESTRESC as "NEGATIVE". If OEORRES is numeric, OESTRESC is a copy of 
OEORRES. 
Exp 
OESTRESN  Numeric Result/Finding in 
Standard Units 
Num    Result 
Qualifier 
Used for continuous or numeric results or findings in standard format; copied in 
numeric format from OESTRESC. OESTRESN should store all numeric test 
results or findings.  
Exp 
OESTRESU  Standard Units  Char  (UNIT)  Variable 
Qualifier 
Standardized units used for OESTRESC and OESTRESN. Example: mol/L.  Exp 
OESTNRLO  Normal Range Lower 
Limit-Standard Units 
Num    Variable 
Qualifier 
Lower end of normal range or reference range for standardized results (e.g., 
OESTRESC, OESTRESN) represented in standardized units (OESTRESU). 
Perm 
OESTNRHI  Normal Range Upper Limit-
Standard Units 
Num    Variable 
Qualifier 
Upper end of normal range or reference range for standardized results (e.g., 
OESTRESC, OESTRESN) represented in standardized units (OESTRESU). 
Perm 
OESTNRC  Normal Range for Character 
Results 
Char    Variable 
Qualifier  
Normal range or reference range for results stored in OESTRESC that are character 
in ordinal or categorical scale. Example: Negative to Trace. 
Perm 
OENRIND  Normal/Reference Range 
Indicator 
Char  (NRIND)  Variable 
Qualifier 
Used to indicate the value is outside the normal range or reference range. May be 
defined by OEORNRLO and OEORNRHI or other objective criteria. Examples: Y, 
N; HIGH, LOW; NORMAL; ABNORMAL. 
Perm 
OERESCAT  Result Category  Char    Variable 
Qualifier 
Used to categorize the result of a finding or medical status per interpretation of test 
results. Example: “POSITIVE”, “NEGATIVE. 
The variable OERESCAT is not meant to replace the use of OENRIND for cases 
where normal ranges are provided. 
Perm 
OESTAT  Completion Status  Char  (ND)  Record 
Qualifier 
Used to indicate that a question was not asked or a test was not done, or a test was 
attempted but did not generate a result. Should be null or have a value of NOT 
DONE. 
Perm 
OEREASND  Reason Not Done  Char    Record 
Qualifier 
Reason not done. Used in conjunction with OESTAT when value is NOT DONE.  Perm 
OEXFN  External File Path  Char    Record 
Qualifier 
Filename for an external file, such as one for an ECG waveform or a medical 
image. 
Perm 
KT 
Delete 
OELOC  Location Used for the 
Measurement 
Char  (LOC)  Record 
Qualifier 
Anatomical location of the subject relevant to the collection of the measurement. 
Examples: EYE for a finding record relative to the complete eye, RETINA for a 
measurement or assessment of only the RETINA. 
See Section 4.1.5.1.2 Tests Not Done and associated example included in the 
attachment for an example on when LOC=EYE may be applicable.   
Perm 
OELAT  Laterality  Char  (LAT)  Variable 
Qualifier 
Qualifier for anatomical location or specimen further detailing laterality. Examples: 
RIGHT, LEFT, BILATERAL 
Perm 
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Variable 
Name 
Variable Label  Type  Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
OEDIR  Directionality  Char  (DIR)  Variable 
Qualifier 
Qualifier for anatomical location or specimen further detailing directionality. 
Examples: ANTERIOR, LOWER, PROXIMAL. 
 
Perm 
OEPORTOT  Portion or Totality   Char  *  Variable 
Qualifier  
Qualifier for anatomical location or specimen further detailing the distribution, 
which means arrangement of, apportioning of. . Examples: ENTIRE, SINGLE, 
SEGMENT, MANY. 
Perm 
OEMETHOD  Method of Test or 
Examination 
Char  (METHOD)  Record 
Qualifier 
Method of the test or examination. Examples: ETDRS for 
OETESTCD=NUMLCOR; CIRRUS OCT, STRATUS OCT, SPECTRAL DOMAIN 
OCT for Optical Coherence Tomography (OCT) methods. 
The different methods may offer different functionality or granularity, affecting the 
set of results and associated meaning. 
See Notes for OETEST.   
Exp 
OERUNID   Run ID   Char     Record 
Qualifier 
A unique identifier for a particular run of a test or evaluation.  Perm 
OEBLFL  Baseline Flag  Char  (NY)  Record 
Qualifier 
Indicator used to identify a baseline value. Should be Y or null.   
OEDRVFL  Derived Flag  Char  (NY)  Record 
Qualifier 
Used to indicate a derived record (e.g., a record that represents the average of other 
records such as a computed baseline). Should be Y or null.  
Perm 
OEEVAL  Evaluator  Char  *  Record 
Qualifier 
Role of the person who provided the evaluation. Used only for results that are 
subjective (e.g., assigned by a person or a group). Examples: ADJUDICATION 
COMMITTEE, INDEPENDENT ASSESSOR, RADIOLOGIST. 
Exp 
OEEVALID  Evaluator Identifier  Char    Variable 
Qualifier 
Used to distinguish multiple evaluators with the same role recorded in OEEVAL. 
Examples: RADIOLOGIST1 or RADIOLOGIST2 
Perm 
OEACPTFL  Accepted Record Flag  Char    Record 
Qualifier 
In cases where more than one assessor provides an evaluation of a result or 
response, this flag identifies the record that is considered, by an independent 
assessor, to be the accepted evaluation. Expected to be Y or null. 
Perm 
VISITNUM  Visit Number  Num    Timing  Clinical encounter number. Numeric version of VISIT, used for sorting.   Exp 
VISIT  Visit Name  Char    Timing  Protocol-defined description of a clinical encounter.  Exp 
VISITDY  Planned Study Day of Visit  Num    Timing  Planned study day of VISIT. Should be an integer.  Perm 
EPOCH  Epoch  Char    Timing  Epoch associated with the start date/time of the observation, or the date/time of 
collection if start date/time is not collected. (See Section 3.2.2). 
Perm 
OEDTC  Date/Time of Collection  Char  IS0 8601  Timing  Collection date and time of an observation represented in IS0 8601 character 
format.  
Exp 
OETPT  Planned Time Point Name  Char    Timing  Text description of time when a measurement or observation should be taken as 
defined in the protocol. This may be represented as an elapsed time relative to a 
fixed reference point, such as time of last dose. See OETPTNUM and OETPTREF. 
Perm 
OETPTNUM  Planned Time Point 
Number 
Num    Timing  Numeric version of planned time point used in sorting.  Perm 
OETPTREF  Time Point Reference  Char    Timing  Description of the fixed reference point referred to by OEELTM, OETPTNUM, 
and OETPT. Examples: PREVIOUS DOSE, PREVIOUS MEAL. 
Perm 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
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OE – Assumptions for Ophthalmic Examinations Domain Model 
1.  This specialized domain includes findings for all physiological ophthalmic examinations, regardless of its origin; i.e., collected on a CRF, received from a 
central provider or vendor, or assessed by other means.  
a.  All morphological ophthalmic examinations are expected to be included in the MO domain. However, the guidelines and assumptions applicable to 
the OE domain are to be applicable to the ophthalmic examinations included in the MO domain in such a way that a combined logical view of all 
ophthalmic examinations can be created at any time without conflict on the use of the variables included. 
2.  The variable LOCID (Location Identifier) is being evaluated for addition to the version of SDTM in which this IG is based on. It is intended to be allowed in 
all subject-level domains. In ophthalmic studies, LOCID will be used to represent the terms OD, OS, OU. These terms are the exclusively preferred terms 
used by the ophthalmology community as abbreviations for the expanded Latin terms listed below. The meaning for each term is included in parenthesis. 
Note that the use of this variable is expected in the OE and MO domains for ophthalmic examinations. OELOC, OELAT and OEDIR are permissible for 
other uses, in particular the ability of specifying detailed locations and performing queries at an aggregate level. 
OD: Oculus Dexter (Right Eye) 
OS: Oculus Sinister (Left Eye) 
OU: Oculus Uterque (Both Eyes) 
3.  The variable LOCID is used as an identifier to group ophthalmic findings and NOT to indicate which eye is randomized separately. The eye(s) that will be 
determined to be the subject of analysis in the trial, is (are) determined based on evaluation of ophthalmic findings according to the protocol. 
4.  The approach followed in the use of CAT and SCAT variables for ophthalmic examinations is: 
a.  For morphological examinations, use –CAT to indicate the segment of the eye that groups the examinations and –SCAT as a further sub-
classification when needed. For the most part, it would coincide with the way CRFs are normally designed to follow the sequence in the process of 
examination. The following would be suggested –CAT/--SCAT values (displayed in title case in this document for readability): 
i.  Anterior Segment Examination 
1.  External 
2.  Anterior Chamber 
3.  Posterior Chamber 
ii.  Posterior Segment Examination 
b.  For functional examinations, use –CAT to indicate the function that correspond to the object of the test and –SCAT as a further sub-classification 
when needed. The following would be suggested –CAT values: 
i.  Visual Acuity 
1.  High Contrast 
2.  Low Contrast 
ii.  Contrast Sensitivity 
iii.  Color Vision 
iv.  Visual Field 
v.  Ocular Comfort 
vi.  [Other functional groups] 
Functional exams may also appear in the CRFs to follow the sequence in the process of examination; however, those will be differentiated from 
the morphological examinations in that generally functional exams involve subjects answering questions [and evaluator providing 
observations].   
© 2014 Clinical Data Interchange Standards Consortium, Inc. All rights reserved   OE - Page 5 
Draft  May 01, 2014 SDTMIG Draft Domain: Ophthalmic Examinations (OE) 
c.  For evaluations that may result from the combined assessments of results from other ophthalmic examinations, use –CAT to indicate that it is an 
overall evaluation and –SCAT as a further sub-classification when needed. The following would be suggested –CAT values: 
i.  Overall Evaluation 
5.  When procedures are performed on the eye: 
a.  The MO domain is expected to contain the test results for structural measurements associated to those procedures. 
i.  For instance, the MO domain would contain structural measurements and interpretation from procedure images whether assessed by a 
specialist or using device software. Refer to the OCT examples shown in Section OE – Examples for Ophthalmic Examinations Domain 
Model. 
b.  The OE domain is expected to contain the test results for physiological assessments associated to those procedures. 
i.  For instance, the OE domain would contain the results of the Visual Acuity assessments. Refer to the Visual Acuity examples shown in 
Section OE – Examples for Ophthalmic Examinations Domain Model. 
c.  The PR (Procedures) domain is expected to contain the information on the procedure performed, in particular the start and end dates and times of 
the procedure (i.e., OCT, MRI, Fundus Photography, etc.), the occurrence or not for pre-specified procedures and reason a procedure does not occur 
if pre-specified; plus the device ID when device information is collected. 
d.  When information on devices used in the study is collected: 
i.  The DI (Study Device Identifiers) domain is expected to contain general device identification. 
ii.  The DU (Device In-Use) domain is expected to contain information on device settings used on a given procedure, when settings used are 
collected and the device has setting options available. The DO (Device Properties) domain may be added to include the different properties 
and device setting available.    
1.  Note that many devices come with options to adjust settings for a particular property at time of use; i.e., adjust the field strength 
when performing an MRI procedure on a subject at a given date and time. In this case, the field strength corresponding to an 
image produced by the device on the corresponding procedure, for a given subject, would be naturally captured in the DU domain 
as opposed to a supplemental qualifier variable on the OE or MO domains. 
2.  When DO is included and there are no optional settings or when individual settings are specified by protocol to be the same for 
each use of the device, there is no need to capture individual device use since the date of the procedure is expected to be in PR. 
e.  The RELREC dataset should be used to describe the associations including those provided using --LNKID variables. 
6.  A value derived by a central provider or vendor according to their procedures is considered collected rather than derived. See Section 4: 4.1.18.1, Origin 
Metadata for Variables. 
7.  This domain does not include eye examinations when those occur as part of a standard general physical examination and no specialized ophthalmic exams 
are performed in the trial. The Physical Examination (PE) domain will be used in those cases to report abnormalities or normal condition. 
8.  Sample collection, (e.g. microbiology for conjunctivitis) will go on to MB domain and not in the OE or MO domains. 
9.  Variables allowed in SDTM 1.4 and not included in the OE - Specification for Ophthalmic Examinations Domain Model section and not listed in next 
assumption are considered permissible in the OE domain. 
10.  The following Qualifiers would not generally be used in OE: --MODIFY, --POS, -BODSYS, --LOINC, --SPEC, --ANTREG, --SPCCND, --SPCUFL, -
LEAD, --CSTATE,  --FAST, --TOX, --TOXGR, --DTHREL, --LLOQ, --ULOQ, --EXCLFL, --REASEX, --DETECT 
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